Lucky for some: the 13th LCA gene

Article

A new gene has been discovered which, when mutated, causes Leber's congenital amaurosis (LCA), a common form of inherited blindness in babies.

A new gene has been discovered which, when mutated, causes Leber's congenital amaurosis (LCA), a common form of inherited blindness in babies, according to a report in the June issue of Nature Genetics.

The gene (LCA5), discovered by researchers from the University of Leeds, UK is the thirteenth gene to be linked to LCA and is involved in the production of lebercilin, an essential component of photoreceptors in the retina. Although lebercilin is also found in other tissues, mutations in the LCA5 gene only appear to cause defects in the retina.

These mutations are relatively rare as LCA5 is a recessive gene, which means a child would need to be carrying two copies of it to develop LCA; one from each parent. The disorder is more common, however, in populations where marriage to first and second cousins are common.

Clinical trials, which are being run by scientists at Moorfields Eye Hospital, London, UK are already underway involving the injection of genes into the eyes of patients with LCA to help restore their sight.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.